Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $260

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $253 to $260.